Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent
SUMMARY We report on the use of a new orally active fungicidal agent, terbinafine (SF 86–327, Lamisil) in the treatment of patients with dermatophyte onychomycosis. Twenty patients with toe‐nail, and 10 with finger‐nail infection received 250 mg of terbinafine daily: finger‐nail infections were trea...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 1989-12, Vol.121 (6), p.753-757 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 757 |
|---|---|
| container_issue | 6 |
| container_start_page | 753 |
| container_title | British journal of dermatology (1951) |
| container_volume | 121 |
| creator | GOODFIELD, M.J.D. ROWELL, N.R. FORSTER, R.A. EVANS, E.G.V. RAVEN, A. |
| description | SUMMARY
We report on the use of a new orally active fungicidal agent, terbinafine (SF 86–327, Lamisil) in the treatment of patients with dermatophyte onychomycosis. Twenty patients with toe‐nail, and 10 with finger‐nail infection received 250 mg of terbinafine daily: finger‐nail infections were treated for 6 months and toe‐nail infections for 12 months. All 24 patients who completed the course of therapy achieved mycological cure, as did two subjects who dropped out of the trial. All but two patients had clinically normal nails at the end of the study period. The mean time for mycological cure was 12.5 weeks for finger‐nail infection, and 24 weeks for toe‐nail infections. The time for a clinical cure with normal nails was 20.5 weeks for finger‐nail infection, and 44 weeks for toe‐nail infection. An exacerbation of pre‐existing dyspepsia occurred in three of the six patients who did not complete the trial but there were no other significant adverse reactions. |
| doi_str_mv | 10.1111/j.1365-2133.1989.tb08217.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1758240018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1758240018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3843-62bf62ad1dd2ad1523ad5d147b0c5fdae726eafd669022e955d0b649a1dffba3</originalsourceid><addsrcrecordid>eNqVUU2P0zAUjBBoKQs_AclCHBZpU_xRxwkHJFjoAuqCKJU4Wi_xc-uSJsV22fYn8K9x1Kp3fHg-zLyZp5kse8HomKX3ej1mopA5Z0KMWVVW41jTkjM13j_IRmfoYTailKqcVoV4nD0JYU0pE1TSi-yCS8ErrkbZ34VHiBvsIuktMeg3EPvt6hCRuM5iE13fDUhcIbGuW6LPCXSGxB7zDlwbyL2LKxLR166DxEBy9WNKyiIXXF2TGWxccO2r67REeg9teyCQRP8ktV23dI0z0BJYJv-n2SMLbcBnp_8yW0w_Lm4-5bNvt59v3s3yRpQTkRe8tgUHw4wZpuQCjDRsomraSGsAFS8QrCmKinKOlZSG1sWkAmasrUFcZldH2a3vf-8wRJ0ubLBtocN-FzRTsuSTlFSZqG-O1Mb3IXi0euvdBvxBM6qHIvRaD2nrIW09FKFPReh9Wn5-8tnVGzTn1VPyCX95wiE00FoPXePCmVaoUirFEu3tkXbvWjz8xwH6_ZcPSookkB8FXIi4PwuA_5U8hJL659db_X0-n4q7O6nn4h_5ibT-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1758240018</pqid></control><display><type>article</type><title>Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>GOODFIELD, M.J.D. ; ROWELL, N.R. ; FORSTER, R.A. ; EVANS, E.G.V. ; RAVEN, A.</creator><creatorcontrib>GOODFIELD, M.J.D. ; ROWELL, N.R. ; FORSTER, R.A. ; EVANS, E.G.V. ; RAVEN, A.</creatorcontrib><description>SUMMARY
We report on the use of a new orally active fungicidal agent, terbinafine (SF 86–327, Lamisil) in the treatment of patients with dermatophyte onychomycosis. Twenty patients with toe‐nail, and 10 with finger‐nail infection received 250 mg of terbinafine daily: finger‐nail infections were treated for 6 months and toe‐nail infections for 12 months. All 24 patients who completed the course of therapy achieved mycological cure, as did two subjects who dropped out of the trial. All but two patients had clinically normal nails at the end of the study period. The mean time for mycological cure was 12.5 weeks for finger‐nail infection, and 24 weeks for toe‐nail infections. The time for a clinical cure with normal nails was 20.5 weeks for finger‐nail infection, and 44 weeks for toe‐nail infection. An exacerbation of pre‐existing dyspepsia occurred in three of the six patients who did not complete the trial but there were no other significant adverse reactions.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/j.1365-2133.1989.tb08217.x</identifier><identifier>PMID: 2532927</identifier><identifier>CODEN: BJDEAZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Adult ; Aged ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal agents ; Antifungal Agents - therapeutic use ; Biological and medical sciences ; Dyspepsia - chemically induced ; Female ; Foot Dermatoses - drug therapy ; Hand Dermatoses - drug therapy ; Humans ; Male ; Medical sciences ; Middle Aged ; Naphthalenes - administration & dosage ; Naphthalenes - adverse effects ; Naphthalenes - therapeutic use ; Onychomycosis - drug therapy ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Terbinafine ; Time Factors</subject><ispartof>British journal of dermatology (1951), 1989-12, Vol.121 (6), p.753-757</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3843-62bf62ad1dd2ad1523ad5d147b0c5fdae726eafd669022e955d0b649a1dffba3</citedby><cites>FETCH-LOGICAL-c3843-62bf62ad1dd2ad1523ad5d147b0c5fdae726eafd669022e955d0b649a1dffba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2133.1989.tb08217.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2133.1989.tb08217.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6785771$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2532927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GOODFIELD, M.J.D.</creatorcontrib><creatorcontrib>ROWELL, N.R.</creatorcontrib><creatorcontrib>FORSTER, R.A.</creatorcontrib><creatorcontrib>EVANS, E.G.V.</creatorcontrib><creatorcontrib>RAVEN, A.</creatorcontrib><title>Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>SUMMARY
We report on the use of a new orally active fungicidal agent, terbinafine (SF 86–327, Lamisil) in the treatment of patients with dermatophyte onychomycosis. Twenty patients with toe‐nail, and 10 with finger‐nail infection received 250 mg of terbinafine daily: finger‐nail infections were treated for 6 months and toe‐nail infections for 12 months. All 24 patients who completed the course of therapy achieved mycological cure, as did two subjects who dropped out of the trial. All but two patients had clinically normal nails at the end of the study period. The mean time for mycological cure was 12.5 weeks for finger‐nail infection, and 24 weeks for toe‐nail infections. The time for a clinical cure with normal nails was 20.5 weeks for finger‐nail infection, and 44 weeks for toe‐nail infection. An exacerbation of pre‐existing dyspepsia occurred in three of the six patients who did not complete the trial but there were no other significant adverse reactions.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Dyspepsia - chemically induced</subject><subject>Female</subject><subject>Foot Dermatoses - drug therapy</subject><subject>Hand Dermatoses - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Naphthalenes - administration & dosage</subject><subject>Naphthalenes - adverse effects</subject><subject>Naphthalenes - therapeutic use</subject><subject>Onychomycosis - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Terbinafine</subject><subject>Time Factors</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVUU2P0zAUjBBoKQs_AclCHBZpU_xRxwkHJFjoAuqCKJU4Wi_xc-uSJsV22fYn8K9x1Kp3fHg-zLyZp5kse8HomKX3ej1mopA5Z0KMWVVW41jTkjM13j_IRmfoYTailKqcVoV4nD0JYU0pE1TSi-yCS8ErrkbZ34VHiBvsIuktMeg3EPvt6hCRuM5iE13fDUhcIbGuW6LPCXSGxB7zDlwbyL2LKxLR166DxEBy9WNKyiIXXF2TGWxccO2r67REeg9teyCQRP8ktV23dI0z0BJYJv-n2SMLbcBnp_8yW0w_Lm4-5bNvt59v3s3yRpQTkRe8tgUHw4wZpuQCjDRsomraSGsAFS8QrCmKinKOlZSG1sWkAmasrUFcZldH2a3vf-8wRJ0ubLBtocN-FzRTsuSTlFSZqG-O1Mb3IXi0euvdBvxBM6qHIvRaD2nrIW09FKFPReh9Wn5-8tnVGzTn1VPyCX95wiE00FoPXePCmVaoUirFEu3tkXbvWjz8xwH6_ZcPSookkB8FXIi4PwuA_5U8hJL659db_X0-n4q7O6nn4h_5ibT-</recordid><startdate>198912</startdate><enddate>198912</enddate><creator>GOODFIELD, M.J.D.</creator><creator>ROWELL, N.R.</creator><creator>FORSTER, R.A.</creator><creator>EVANS, E.G.V.</creator><creator>RAVEN, A.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>198912</creationdate><title>Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent</title><author>GOODFIELD, M.J.D. ; ROWELL, N.R. ; FORSTER, R.A. ; EVANS, E.G.V. ; RAVEN, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3843-62bf62ad1dd2ad1523ad5d147b0c5fdae726eafd669022e955d0b649a1dffba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Dyspepsia - chemically induced</topic><topic>Female</topic><topic>Foot Dermatoses - drug therapy</topic><topic>Hand Dermatoses - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Naphthalenes - administration & dosage</topic><topic>Naphthalenes - adverse effects</topic><topic>Naphthalenes - therapeutic use</topic><topic>Onychomycosis - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Terbinafine</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GOODFIELD, M.J.D.</creatorcontrib><creatorcontrib>ROWELL, N.R.</creatorcontrib><creatorcontrib>FORSTER, R.A.</creatorcontrib><creatorcontrib>EVANS, E.G.V.</creatorcontrib><creatorcontrib>RAVEN, A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GOODFIELD, M.J.D.</au><au>ROWELL, N.R.</au><au>FORSTER, R.A.</au><au>EVANS, E.G.V.</au><au>RAVEN, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>1989-12</date><risdate>1989</risdate><volume>121</volume><issue>6</issue><spage>753</spage><epage>757</epage><pages>753-757</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><coden>BJDEAZ</coden><abstract>SUMMARY
We report on the use of a new orally active fungicidal agent, terbinafine (SF 86–327, Lamisil) in the treatment of patients with dermatophyte onychomycosis. Twenty patients with toe‐nail, and 10 with finger‐nail infection received 250 mg of terbinafine daily: finger‐nail infections were treated for 6 months and toe‐nail infections for 12 months. All 24 patients who completed the course of therapy achieved mycological cure, as did two subjects who dropped out of the trial. All but two patients had clinically normal nails at the end of the study period. The mean time for mycological cure was 12.5 weeks for finger‐nail infection, and 24 weeks for toe‐nail infections. The time for a clinical cure with normal nails was 20.5 weeks for finger‐nail infection, and 44 weeks for toe‐nail infection. An exacerbation of pre‐existing dyspepsia occurred in three of the six patients who did not complete the trial but there were no other significant adverse reactions.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>2532927</pmid><doi>10.1111/j.1365-2133.1989.tb08217.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 1989-12, Vol.121 (6), p.753-757 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1758240018 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents Antifungal Agents - therapeutic use Biological and medical sciences Dyspepsia - chemically induced Female Foot Dermatoses - drug therapy Hand Dermatoses - drug therapy Humans Male Medical sciences Middle Aged Naphthalenes - administration & dosage Naphthalenes - adverse effects Naphthalenes - therapeutic use Onychomycosis - drug therapy Pharmacology. Drug treatments Randomized Controlled Trials as Topic Terbinafine Time Factors |
| title | Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A37%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20dermatophyte%20infection%20of%20the%20finger-%20and%20toe-nails%20with%20terbinafine%20(SF%2086-327,%20Lamisil),%20an%20orally%20active%20fungicidal%20agent&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=GOODFIELD,%20M.J.D.&rft.date=1989-12&rft.volume=121&rft.issue=6&rft.spage=753&rft.epage=757&rft.pages=753-757&rft.issn=0007-0963&rft.eissn=1365-2133&rft.coden=BJDEAZ&rft_id=info:doi/10.1111/j.1365-2133.1989.tb08217.x&rft_dat=%3Cproquest_cross%3E1758240018%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1758240018&rft_id=info:pmid/2532927&rfr_iscdi=true |